While the agency is aware of reports of pets consuming various forms of cannabis, to date, FDA has not directly received any reports of adverse events associated with animals given cannabis products. However, adverse events from accidental ingestion are well-documented in scientific literature. If you feel your animal has suffered from ingesting cannabis, we encourage you to report the adverse event to the FDA. Please visit Reporting Information about Animal Drugs and Devices to learn more about how to report an adverse event related to an animal drug or for how to report an adverse event or problem with a pet food.
When a product is in violation of the FD&C Act, FDA considers many factors in deciding whether or not to initiate an enforcement action. Those factors include, among other things, agency resources and the threat to the public health. FDA also may consult with its federal and state partners in making decisions about whether to initiate a federal enforcement action.
A. The Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA), permits veterinarians to prescribe extralabel uses of approved human and animal drugs for animals under certain conditions. Extralabel use must comply with all the provisions of AMDUCA and its implementing regulation at 21 CFR § 530. Among other limitations, these provisions allow extralabel use of a drug only on the lawful order of a licensed veterinarian in the context of a valid veterinarian-client-patient relationship and only in circumstances when the health of an animal is threatened or suffering, or death may result from failure to treat.
Children and Pregnant/Lactating Women
A. The FDA is aware that several states have either passed laws that remove state restrictions on the medical use of cannabis and its derivatives or are considering doing so. It is important to conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. We welcome the opportunity to talk with states who are considering support for medical research of cannabis and its derivatives, so that we can provide information on Federal and scientific standards.
A. At the federal level, the Agriculture Improvement Act of 2018, Pub. L. 115-334, (the 2018 Farm Bill) was signed into law on Dec. 20, 2018. Among other things, this new law changes certain federal authorities relating to the production and marketing of hemp, defined as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.” These changes include removing hemp from the CSA, which means that cannabis plants and derivatives that contain no more than 0.3 percent THC on a dry weight basis are no longer controlled substances under federal law.
The FDA will continue to facilitate the work of companies interested in appropriately bringing safe, effective, and quality products to market, including scientifically-based research concerning the medicinal uses of cannabis. Additional information concerning research on the medical use of cannabis is available from the National Institutes of Health, particularly the National Cancer Institute (NCI) and National Institute on Drug Abuse (NIDA).
FDA relies on applicants and scientific investigators to conduct research. The agency’s role, as laid out in the FD&C Act, is to review data submitted to the FDA in an application for approval to ensure that the drug product meets the statutory standards for approval.
Even with the Farm Bill provision, state or local governments can impose stricter limitations, Miller says. Right now, about 15 states have “pretty strong pro-hemp CBD statues. All the rest are vague or silent.”
Jonathan Miller, JD, general counsel for the U.S. Hemp Roundtable, an industry group, says, “I’ve never heard of anyone being arrested for buying CBD online.” He has heard about store owners selling CBD products being cited.
“It is going to bring some level of clarity to this market,” NORML’s Armentano says.
What About CBD Products?
The list of states where medical or recreational use of marijuana and CBD is legal keeps growing. Thirty-three states and Washington, D.C., have passed medical marijuana laws (including 10 states and the nation’s capital where recreational and medical use is legal), says Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML). Also, 14 states have enacted CBD-explicit medical laws.
Jan. 8, 2019 — As the legalized cannabis industry in the United States grows with nearly every election, consumers interested in these products have more and more options. But they might also have more questions, given the different sources of the products, the difference in federal and state laws, and the difference between those that make you high and those that don’t.
And, according to Armentano, all cannabis products, including marijuana and medical CBD, are illegal in Idaho, South Dakota, and Nebraska.
CBD products sold online run the gamut, from tinctures and creams, to gummies and pills, to coffees and teas. Most experts believe the Farm Bill makes it clear that consumers anywhere can legally buy these products if they’re made from low- or zero-THC hemp. But that could change if your state’s lawmakers explicitly act to ban them.